Right Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level

NCT07046312 | Not Yet Recruiting

• 1 other identifier: MD13/2025
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain echocardiography

Conditions

Psoriatic Arthritis (PsA); Subclinical Right Ventricular Systolic Dysfunction

Outcome Measures

Primary Outcomes (1)

• Detecting subclinical right ventricular systolic dysfunction in PsA patients

  Detecting subclinical right ventricular systolic dysfunction in PsA using 2D strain transthoracic echo and its relation to serum endostatin level

  Up to 24 months

Study Arms (2)

Control

30 control group matched as regards BMI, age and sex will be subjected to transthoracic echo and measuring serum endostatin level.

Cases of Psoriatic arthritis patients

30 PsA patients will be subjected to transthoracic echo, measuring serum endostatin level and modified composite psoriatic disease activity index

Eligibility Criteria

• Age: 20 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

30 patients with PsA and 30 matched healthy controls

You may qualify if:

• Psoriatic arthritis patients according to CASPAR criteria
• Psoriatic arthritis patients without overt cardiovascular symptoms
• Patients with age between 20 to 50 years of age

You may not qualify if:

• Other systemic autoimmune diseases
• Patients with a history of known valvular disease, atrial fibrillation or any other arrhythmia , heart failure, ischemic cardiomyopathy severe obstructive pulmonary diseases and metabolic syndrome.
• Patients with medical disorders as renal, congenital heart diseases, hematological disorders and cancer patients.
• Patients taking certain drugs that have been confirmed to be risk factors for PAH such as appetite suppressant intake drugs (aminorex, fenfluramine derivatives and benfluorex) and chemotherapeutic agents.
• Family history of myocardial infarction, cerebrovascular disease or sudden death before the age of 65y in females and 55 y in males.

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Ain Shams University

Cairo, Abbassia, 00202, Egypt

Location

MeSH Terms

Conditions

Arthritis, Psoriatic

Condition Hierarchy (Ancestors)

Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Dina Maamoun ElHadba, MSc Ain Shams University

CONTACT

01006780166; DinaElhadba@med.asu.edu

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 19, 2025
• First Posted: July 1, 2025
• Study Start: July 1, 2025
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): April 1, 2027
• Last Updated: July 1, 2025

Record last verified: 2025-05

Locations

EG (1)